Interleukin-10 genetically modified clinical-grade mesenchymal stromal cells markedly reinforced functional recovery after spinal cord injury via directing alternative activation of macrophages.

Abstract

BACKGROUND:

After spinal cord injury (SCI), dysregulated or nonresolving inflammatory processes can severely disturb neuronal homeostasis and drive neurodegeneration. Although mesenchymal stromal cell (MSC)-based therapies have showed certain therapeutic efficacy, no MSC therapy has reached its full clinical goal. In this study, we examine interleukin-10 (IL10) genetically modified clinical-grade MSCs (IL10-MSCs) and evaluate their clinical safety, effectiveness, and therapeutic mechanism in a completely transected SCI mouse model.

METHODS:

We established stable IL10-overexpressing human umbilical-cord-derived MSCs through electric transduction and screened out clinical-grade IL10-MSCs according to the criteria of cell-based therapeutic products, which were applied to mice with completely transected SCI by repeated tail intravenous injections. Then we comprehensively investigated the motor function, histological structure, and nerve regeneration in SCI mice, and further explored the potential therapeutic mechanism after IL10-MSC treatment.

RESULTS:

IL10-MSC treatment markedly reinforced locomotor improvement, accompanied with decreased lesion volume, regeneration of axons, and preservation of neurons, compared with naïve unmodified MSCs. Further, IL10-MSC transplantation increased the ratio of microglia to infiltrated alternatively activated macrophages (M2), and reduced the ratio of classically activated macrophages (M1) at the injured spinal cord, meanwhile increasing the percentage of Treg and Th2 cells, and reducing the percentage of Th1 cells in the peripheral circulatory system. In addition, IL10-MSC administration could prevent apoptosis and promote neuron differentiation of neural stem cells (NSCs) under inflammatory conditions in vitro.

CONCLUSIONS:

IL10-MSCs exhibited a reliable safety profile and demonstrated promising therapeutic efficacy in SCI compared with naïve MSCs, providing solid support for future clinical application of genetically engineered MSCs.

• Authors: Tianyun Gao, Feifei Huang, Wenqing Wang, Yuanyuan Xie, Bin Wang
• Journal: Cellular & molecular biology letters (Cell Mol Biol Lett) Vol. 27 Issue 1 Pg. 27 (Mar 17 2022) ISSN: 1689-1392 [Electronic] England
• PMID: 35300585 (Publication Type: Journal Article)
• Copyright: © 2022. The Author(s).

Chemical References

• Interleukin-10

Topics

• Animals
• Interleukin-10 (genetics, therapeutic use)
• Macrophages (metabolism, physiology)
• Mesenchymal Stem Cell Transplantation
• Mesenchymal Stem Cells
• Mice
• Spinal Cord Injuries (pathology, therapy)